In this episode, we speak to Dr. Nikolai Naoumov, MD, PhD, FRCP, FRCPAth, FAASLD (Adviser for Clinical Research and Drug Development in Liver Diseases at Novartis, and physician-scientist and specialist in liver diseases).
Episode 4 with Dr. Nikolai Naoumov - Dialogues on AI Digital Pathology.
Introduction of Dr. Nikolai Naoumov
Dr. Nikolai Naoumov,Ph.D.
Development in Liver Diseases at Novartis, and physician-scientist and specialist in liver diseases.
Dr Nikolai Naoumov is an Adviser for Clinical Research and Drug Development in Liver Diseases at Novartis. Additionally, Nikolai has been an adviser for research organizations, pharma companies, the Foundations for Liver Research in the UK and in Switzerland.
Nikolai is a physician-scientist with a professional career combining academic research, clinical care and drug development – all focused on liver diseases. He is a Fellow of the Royal College of Physicians (London) and also the Royal College of Pathologists (UK), and has led research teams at King’s College Liver Unit and subsequently as Professor of Hepatology at University College London.
▲ A picture of Nikolai Naoumov, Ph.D.
Nikolai’s experience at the Novartis headquarters in Basel, Switzerland, stems from all stages of drug development, and leadership of global cross-functional teams and programs. He set-up and led the Therapeutic Area Hepatology with a broad portfolio in non-viral liver diseases.
With his current work focusing on digital pathology with AI assessment of liver biopsies, NASH combination therapies, HBV cure and liver fibrosis, Nikolai is here to talk about the impact of AI digital pathology in drug development efforts for NASH.
往期内容
大咖对话第1期（音频）：Stephen Harrison博士-AI数字病理学的对话
大咖对话第2期（音频）：David Kleiner博士和Dean Tai博士-AI数字病理学的对话
大咖对话第3期（音频）：Suneil Hosmane博士-AI数字病理学的对话
关于我们
新加坡医疗科技公司HistoIndex，是杭州筹图科技有限公司的母公司，我们利用人工智能的图像分析技术和全球独创的无染色成像技术相结合应用于疾病进展的评价，特别是NASH新药开发的病理评价中。目前该技术平台已经在NASH临床前的多个动物模型和多个II，III期临床试验上做了深入研究和算法验证，已经参与完成近四十家国际国内知名药企、大型CRO公司和科研机构主办的相关试验。
